We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Clinigen Group Plc | LSE:CLIN | London | Ordinary Share | GB00B89J2419 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 925.00 | 924.50 | 925.00 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
03/11/2017 16:28 | Depends on your quantum purchase price | r ball | |
03/11/2017 10:47 | does anyone know what is the book price per unit frothose like me who were in quantum phrma as my broker did not enter a price please | ali47fish | |
23/10/2017 14:39 | surely a great acquisition today of 'largest supplier of unlicensed medicines'. complements launch of 'Japanese business in October 2016'. 'Japan is the world's second largest pharmaceutical market. The unlicensed medicines market in Japan is underdeveloped'. 'The threat of counterfeit medicines entering the supply chain in Japan, also remains an issue. Japan is the second-largest target of illegal online medicine sellers in the world behind the US.' All IMHO. | mfhmfh | |
10/10/2017 11:22 | 'Peel Hunt today upgrades its investment rating on Clinigen Group (LON:CLIN) to buy (from add) and raised its price target to 1350p (from 1200p).' | mfhmfh | |
28/9/2017 09:54 | solid results today. bullish about the future. 'Net debt substantially decreased by £33.1m to £35.0m (2016: £68.1m)' All IMHO. | mfhmfh | |
16/8/2017 12:12 | possible offer for QP. | mfhmfh | |
08/8/2017 10:50 | A good rns and well through 1000p now | jimbowen30 | |
08/8/2017 08:58 | positive RNS today | mfhmfh | |
03/8/2017 05:40 | Write-up in today's Shares mag. along with OXB and ABZ | gersemi | |
27/7/2017 17:05 | AIM pharma flavour of the month. Also in SLN and was in Abcam until yesterday. Maybe sold too soon. | volsung | |
22/7/2017 13:13 | I am liking the breakout. | volsung | |
19/7/2017 10:54 | Indeed a very positive update. I'm sure this will break 1,000p and more once investors start focusing on 2018/2019 earnings forecasts. | jimbowen30 | |
18/7/2017 08:16 | Positive update IMHO. Let's try to break 1,000p. | mfhmfh | |
07/7/2017 20:31 | New all time high today. | jimbowen30 | |
07/7/2017 11:24 | Thanks that's a big change in target | nfs | |
07/7/2017 10:55 | 'Peel Hunt today reaffirms its buy investment rating on Clinigen Group (LON:CLIN) and raised its price target to 1200p (from 1015p).' | mfhmfh | |
17/4/2017 02:21 | Just watch out for continually heavy selling from Andrew Leaver and connections as they run down their founding stake.I got in and out as the share price takes 2 steps forward and 2-3 steps back. When the sell off is done it should be a good investment. All imo. | shaker44 | |
17/4/2017 01:28 | Have recently started looking at CLIN. Any thoughts or current views on the company? | jimbowen30 | |
16/3/2017 10:34 | Clinigen CEO Shaun Chilton will be presenting to investors at the upcoming Proactive One2One Forum taking place on the evening of 23rd March from 6pm. For more details and registration, please click here: | aim_trader | |
25/1/2017 15:50 | IC are positive about CLIN today. | mfhmfh | |
25/1/2017 13:00 | N+1 Singer: 895p Peel Hunt: 1000p Numis: 933p | mfhmfh | |
24/1/2017 16:23 | Half Year Trading Update according to website... | mfhmfh | |
11/1/2017 15:57 | Nice rise and high volumeGood sign | nfs | |
05/1/2017 10:51 | I certainly think 900p is a fair price for this company. Shire (SHP) is another I think is worth buying right now. All IMHO. | mfhmfh |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions